MA30988B1 - Composes destines a inhiber la progression mitotique - Google Patents

Composes destines a inhiber la progression mitotique

Info

Publication number
MA30988B1
MA30988B1 MA31985A MA31985A MA30988B1 MA 30988 B1 MA30988 B1 MA 30988B1 MA 31985 A MA31985 A MA 31985A MA 31985 A MA31985 A MA 31985A MA 30988 B1 MA30988 B1 MA 30988B1
Authority
MA
Morocco
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
cancer
treatment
Prior art date
Application number
MA31985A
Other languages
English (en)
French (fr)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30988(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA30988B1 publication Critical patent/MA30988B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA31985A 2006-11-16 2009-06-12 Composes destines a inhiber la progression mitotique MA30988B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
MA30988B1 true MA30988B1 (fr) 2009-12-01

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31985A MA30988B1 (fr) 2006-11-16 2009-06-12 Composes destines a inhiber la progression mitotique

Country Status (34)

Country Link
US (7) US8026246B2 (cg-RX-API-DMAC7.html)
EP (4) EP2086981B1 (cg-RX-API-DMAC7.html)
JP (3) JP5102839B2 (cg-RX-API-DMAC7.html)
KR (2) KR101110458B1 (cg-RX-API-DMAC7.html)
CN (2) CN103483343B (cg-RX-API-DMAC7.html)
AR (1) AR064246A1 (cg-RX-API-DMAC7.html)
AT (1) ATE556076T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007322046B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718803B8 (cg-RX-API-DMAC7.html)
CA (1) CA2669680C (cg-RX-API-DMAC7.html)
CL (1) CL2007003244A1 (cg-RX-API-DMAC7.html)
CR (3) CR10782A (cg-RX-API-DMAC7.html)
CY (1) CY1112828T1 (cg-RX-API-DMAC7.html)
DK (2) DK2497772T3 (cg-RX-API-DMAC7.html)
EA (1) EA015779B1 (cg-RX-API-DMAC7.html)
ES (3) ES2384123T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20125459B (cg-RX-API-DMAC7.html)
HR (2) HRP20120490T1 (cg-RX-API-DMAC7.html)
IL (1) IL198690A0 (cg-RX-API-DMAC7.html)
MA (1) MA30988B1 (cg-RX-API-DMAC7.html)
MX (3) MX348568B (cg-RX-API-DMAC7.html)
MY (1) MY153243A (cg-RX-API-DMAC7.html)
NO (1) NO343338B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ577042A (cg-RX-API-DMAC7.html)
PH (1) PH12012502057B1 (cg-RX-API-DMAC7.html)
PL (2) PL2497772T3 (cg-RX-API-DMAC7.html)
PT (2) PT2497772E (cg-RX-API-DMAC7.html)
RS (2) RS52313B (cg-RX-API-DMAC7.html)
SG (2) SG176443A1 (cg-RX-API-DMAC7.html)
SI (2) SI2497772T1 (cg-RX-API-DMAC7.html)
TW (1) TWI401255B (cg-RX-API-DMAC7.html)
UA (1) UA94129C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008063525A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903279B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511139B8 (pt) * 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
CN102264368B (zh) * 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2526671T3 (es) * 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
EP3347350A1 (en) 2015-09-09 2018-07-18 Icahn School of Medicine at Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
CA3017411C (en) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024006424A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Kras g12c inhibitor for treating cancer
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CA2305307C (en) 1997-09-29 2004-11-30 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60039782D1 (de) 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
PT1355905E (pt) * 2000-12-21 2007-05-31 Vertex Pharma Compostos de pirazole úteis como inibidores de proteínaquinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
MXPA04001252A (es) 2001-08-09 2004-05-27 Actelion Pharmaceuticals Ltd Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
BRPI0511139B8 (pt) 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
AU2005306458B2 (en) 2004-11-17 2011-02-17 Miikana Therapeutics, Inc. Kinase inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
JP5140600B2 (ja) 2005-12-23 2013-02-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー オーロラキナーゼのアザインドール阻害薬
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
BRPI0718803B8 (pt) 2021-05-25
EP2497773B1 (en) 2015-02-25
JP2014055166A (ja) 2014-03-27
US9765076B2 (en) 2017-09-19
RS53788B1 (sr) 2015-06-30
AU2007322046A1 (en) 2008-05-29
ES2384123T3 (es) 2012-06-29
US20190031662A1 (en) 2019-01-31
CN103483343A (zh) 2014-01-01
PL2497772T3 (pl) 2015-05-29
WO2008063525A1 (en) 2008-05-29
BRPI0718803A2 (pt) 2013-12-03
EA200970486A1 (ru) 2009-10-30
JP2012006965A (ja) 2012-01-12
HK1217699A1 (en) 2017-01-20
GEP20125459B (en) 2012-03-26
EA015779B1 (ru) 2011-12-30
ZA200903279B (en) 2010-07-28
EP2497772B1 (en) 2014-10-29
EP2086981A1 (en) 2009-08-12
US10836766B2 (en) 2020-11-17
MY153243A (en) 2015-01-29
KR101110458B1 (ko) 2012-03-13
NZ611898A (en) 2015-01-30
CN103483343B (zh) 2016-06-01
PL2086981T3 (pl) 2012-09-28
CR10782A (es) 2009-06-24
US8026246B2 (en) 2011-09-27
SI2497772T1 (sl) 2015-03-31
AU2007322046B2 (en) 2012-04-05
CN101547924B (zh) 2013-09-25
JP2010510215A (ja) 2010-04-02
AR064246A1 (es) 2009-03-25
EP2086981B1 (en) 2012-05-02
US20110312942A1 (en) 2011-12-22
NO20091864L (no) 2009-06-15
HK1175777A1 (en) 2013-07-12
DK2497772T3 (en) 2015-01-19
BRPI0718803B1 (pt) 2020-11-17
SG10201503350TA (en) 2015-06-29
CR20140154A (es) 2014-07-23
JP5102839B2 (ja) 2012-12-19
IL198690A0 (en) 2010-02-17
PT2497772E (pt) 2015-02-05
US20240400567A1 (en) 2024-12-05
KR101342014B1 (ko) 2013-12-19
US11958855B2 (en) 2024-04-16
KR20110113210A (ko) 2011-10-14
TWI401255B (zh) 2013-07-11
TW200829589A (en) 2008-07-16
HK1175778A1 (en) 2013-07-12
UA94129C2 (ru) 2011-04-11
KR20090091173A (ko) 2009-08-26
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
US9988384B2 (en) 2018-06-05
HK1134672A1 (en) 2010-05-07
RS52313B (sr) 2012-12-31
EP2944639A1 (en) 2015-11-18
DK2086981T3 (da) 2012-08-06
MX348568B (es) 2017-06-20
PH12012502057A1 (en) 2015-09-14
US20110312943A1 (en) 2011-12-22
US20080167292A1 (en) 2008-07-10
CY1112828T1 (el) 2016-02-10
HRP20120490T1 (hr) 2012-07-31
NZ597252A (en) 2013-06-28
SG176443A1 (en) 2011-12-29
CR20140544A (es) 2015-01-12
EP2497772A1 (en) 2012-09-12
ES2537451T3 (es) 2015-06-08
MX343391B (es) 2016-11-04
PH12012502057B1 (en) 2018-10-24
US20150166545A1 (en) 2015-06-18
JP5452811B2 (ja) 2014-03-26
US20210214361A1 (en) 2021-07-15
CN101547924A (zh) 2009-09-30
CA2669680A1 (en) 2008-05-29
ES2528793T3 (es) 2015-02-12
NO343338B1 (no) 2019-02-04
SI2086981T1 (sl) 2012-12-31
CA2669680C (en) 2012-04-10
EP2944639B1 (en) 2017-01-04
NZ577042A (en) 2012-03-30
ATE556076T1 (de) 2012-05-15
EP2497773A1 (en) 2012-09-12
HRP20150047T1 (en) 2015-03-13
CL2007003244A1 (es) 2008-04-04

Similar Documents

Publication Publication Date Title
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
MA30781B1 (fr) Inhibiteur de kinase
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA29688B1 (fr) Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA32904B1 (fr) Composes de purine
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes